Developer docs
API playgroundTry for free, no card

Search company profiles

Biovian

Full company profile

uuid000b23r

Namestring
Biovian
Legal namestring
3P BIOPHARMACEUTICALS, S.L.U.
Websiteurl
biovian.com
Company typeenum
Private
Founded yearint
2003
Descriptiontext

Biovian, operating commercially as 3PBIOVIAN, is a privately-held biologics Contract Development and Manufacturing Organization (CDMO) headquartered in Turku, Finland with a second manufacturing site in Pamplona-Noáin, Spain. Founded in 2003 and employing 101-250 staff, the company provides end-to-end GMP manufacturing services for biopharmaceutical clients spanning pre-clinical development through commercial supply. Its service portfolio covers four core modalities — recombinant proteins (via both microbial/bacterial and mammalian/CHO expression systems), viral vectors (including adeno-associated virus manufactured through its proprietary AAVion® platform and adenovirus), plasmid DNA, and cell therapies — supplemented by aseptic fill-and-finish, quality control testing, and conjugated biotherapeutics services.

The business model is a B2B fee-for-service CDMO structure, with quote-based project pricing, multi-year contracts, and direct enterprise engagement with biotech and pharmaceutical clients across Europe, the US, and Asia. The go-to-market combines direct field sales with event-driven lead generation at major industry conferences (Nordic Life Science Days, BioProcess International, BIOSPAIN, CPHI) and content-led demand generation on its website and LinkedIn presence. The company received institutional investment from EQT in 2018 and rebranded to the unified 3PBIOVIAN identity in 2024. Legal entity is 3P BIOPHARMACEUTICALS, S.L.U., a Spanish private limited company (Sociedad Limitada Unipersonal). Revenue, ownership composition, and customer-level data are not publicly disclosed.

Short descriptiontext

Biovian (3PBIOVIAN) is a privately-held European biologics CDMO providing GMP contract development and manufacturing services for recombinant proteins, viral vectors (AAV, adenovirus), plasmid DNA, and cell therapies to biotech and pharmaceutical clients globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersTurku, Finland
HQ citystring
Turku
HQ countrystring
Finland
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biologics contract manufacturing, viral vector manufacturing, recombinant protein production, plasmid DNA manufacturing, cell therapy CDMO
Industry5 codes
PRIMARYHLAGAGAB
Gene Therapy CDMO (Viral Vector Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAGAC
mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGAGAL
GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
  • Scientific Research and Development Services5417
SIC code3 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Commercial Physical & Biological Research8731
  • Pharmaceutical Preparations2834
Product category
Biologics Contract Development and Manufacturing
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Contract Manufacturing Services
TypeManaged Services
Description

Biovian generates revenue through contract development and manufacturing services. As a CDMO, they provide fee-for-service manufacturing across the product lifecycle, from pre-clinical and clinical development through commercial manufacturing. Revenue is generated through project-based contracts, long-term manufacturing agreements, and development service contracts with biotech and pharmaceutical clients requiring GMP-compliant production of biologics, viral vectors, plasmid DNA, and cell therapies.

3pbiovian.com
2Development and Testing Services
TypeProfessional Services
Description

Additional revenue streams include process development services, analytical testing and QC services, aseptic fill and finish services, and conjugated biotherapeutics development. These specialized services support the core manufacturing business and provide integrated solutions for clients throughout the drug development journey.

3pbiovian.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Infrastructure, Supply Chain, Technology or R&D, Marketing or Sales
Pricing details1 tier
1Custom project-based pricing for CDMO services
ModelOtherBilling cadenceMulti-year contract
Notes

Quote-based pricing tailored to project requirements, scale, and service scope. Contracts typically span multiple phases from pre-clinical through commercial manufacturing.

3pbiovian.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1AAVion® Platform
Description

Proprietary AAV manufacturing platform for gene therapy vector production.

3pbiovian.com
Core offering1 text field

Biovian (3PBIOVIAN) is a Contract Development and Manufacturing Organization (CDMO) providing GMP-compliant biologics manufacturing services from early-stage development through commercial supply. The company offers integrated services across recombinant proteins (microbial and mammalian), viral vectors (AAV, adenovirus), plasmid DNA, and cell therapies, supported by aseptic fill and finish, QC testing, and conjugated biotherapeutics capabilities. Operations are run from two manufacturing sites in Turku, Finland and Pamplona-Noáin, Spain, serving biotech and pharmaceutical clients globally.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

3PBIOVIAN is a global Contract Development and Manufacturing Organization (CDMO) offering integrated biologics manufacturing services from early-stage development through commercialization. The portfolio spans four core service areas: Proteins (microbial and mammalian expression systems), Viral Vectors (including AAV via the proprietary AAVion® Platform, and adenovirus), Plasmid DNA, and Cell Therapies. These core services are supported by additional capabilities including Aseptic Fill & Finish, QC Services, and Conjugated Biotherapeutics. The company provides end-to-end development and manufacturing for both Drug Substances and Drug Products, serving clients across preclinical, clinical (Phase I-III), and commercial phases. Manufacturing facilities are located in Pamplona-Noáin, Spain and Turku, Finland.

Product and service8 records
1Recombinant Protein Manufacturing
CategoryBioprocess / CDMO Services
Description

GMP-compliant recombinant protein manufacturing services covering microbial (bacterial) and mammalian (CHO) expression systems for pre-clinical, clinical (Phase I-III), and commercial production. Intended for biotech and pharmaceutical companies developing protein-based biologics.

2Viral Vector Manufacturing
CategoryGene Therapy / CDMO Services
Description

GMP viral vector manufacturing services for gene therapy and vaccine development, including adeno-associated virus (AAV) and adenovirus production for pre-clinical through commercial supply. Target customers are gene therapy developers and vaccine developers in biotech and pharma.

3AAVion® AAV Manufacturing Platform
CategoryGene Therapy Platform / Proprietary Technology
Description

Proprietary AAV (Adeno-Associated Virus) manufacturing platform enabling flexible and efficient viral vector production for gene therapy applications. Used as the in-house platform for Biovian's AAV manufacturing service line.

4Plasmid DNA Manufacturing
CategoryBioprocess / CDMO Services
Description

GMP plasmid DNA CDMO services for pre-clinical, clinical, and commercial production following the same GMP standards applied to drug substance and drug product manufacturing. Targeted at developers of gene therapies, DNA vaccines, and cell therapies.

5Cell Therapy Manufacturing
CategoryCell Therapy / CDMO Services
Description

Cell and gene therapy services supporting development, manufacturing, and commercialization of cell-based therapies for biotech and pharmaceutical clients.

6Aseptic Fill & Finish
CategoryDrug Product / Fill-Finish Services
Description

Integrated aseptic fill and finish services for drug products including formulation, terminal sterilization or aseptic processing, visual inspection, in-house sterility testing, labeling, packaging, and Qualified Person (QP) certified release.

7Quality Control (QC) Services
CategoryAnalytical / Quality Services
Description

Quality control testing services supporting biopharmaceutical manufacturing compliance, including analytical and release testing for drug substance and drug product.

8Conjugated Biotherapeutics Manufacturing
CategoryAdvanced Biologics / CDMO Services
Description

Manufacturing services for conjugated biotherapeutics combining biologic components with targeting agents, such as antibody-drug conjugates and related modalities.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global Tier-1 CDMO with massive biologics, viral vector, and cell therapy capacity. Competes head-to-head with Biovian for gene therapy and mammalian protein programs but at vastly larger scale.

TypeBroad incumbent
Description

Large-scale Korean CDMO focused on mammalian biologics manufacturing with rapidly expanding gene therapy services. Represents the scale competition that Biovian faces in winning commercial-stage programs.

TypeBroad incumbent
Description

Global pharma services platform with biologics CDMO, viral vector, and fill-finish capabilities. Competes with Biovian across multiple modalities through its Patheon and Brammer Bio heritage.

TypeDirect peer
Description

Mid-to-large global CDMO offering microbial and mammalian protein, viral vector, and cell therapy services. One of the closest direct peers to Biovian by modality mix and target client base.

TypeDirect peer
Description

European-based CDMO specializing in mammalian cell culture recombinant proteins and gene therapy manufacturing. Closely comparable mid-sized European CDMO competing for the same biotech clients.

TypeBroad incumbent
Description

China-based global biologics CDMO with end-to-end capabilities from cell line development to commercial manufacturing. Direct competitor for biotech outsourcing decisions, including plasmid and viral vector services.

TypeDirect peer
Description

Specialist viral vector CDMO focused on late-stage clinical and commercial GMP manufacturing of oncolytic viruses and viral vaccines. Highly comparable to Biovian's viral vector service line.

8Cobra Biologics (Charles River Laboratories)
TypeDirect peer
Description

European CDMO providing viral vector and plasmid DNA manufacturing services for gene therapy and vaccine clients, now part of Charles River. Closely aligned with Biovian's plasmid and viral vector CDMO offering.

TypeBroad incumbent
Description

Global CDMO with biologics, viral vector, and cell therapy capabilities alongside its dominant fill-finish business. Competes with Biovian for biologics manufacturing and integrated DS-to-DP programs.

10Yposkesi
TypeDirect peer
Description

French gene therapy CDMO producing AAV and lentiviral vectors for clinical and commercial supply. Comparable European specialty viral vector CDMO competing in the same gene therapy client segment as Biovian.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Biovian

Biologics Contract Development and Manufacturingbiovian.com

Biovian (3PBIOVIAN) is a privately-held European biologics CDMO providing GMP contract development and manufacturing services for recombinant proteins, viral vectors (AAV, adenovirus), plasmid DNA, and cell therapies to biotech and pharmaceutical clients globally.

What Biovian does

Biovian, operating commercially as 3PBIOVIAN, is a privately-held biologics Contract Development and Manufacturing Organization (CDMO) headquartered in Turku, Finland with a second manufacturing site in Pamplona-Noáin, Spain. Founded in 2003 and employing 101-250 staff, the company provides end-to-end GMP manufacturing services for biopharmaceutical clients spanning pre-clinical development through commercial supply. Its service portfolio covers four core modalities — recombinant proteins (via both microbial/bacterial and mammalian/CHO expression systems), viral vectors (including adeno-associated virus manufactured through its proprietary AAVion® platform and adenovirus), plasmid DNA, and cell therapies — supplemented by aseptic fill-and-finish, quality control testing, and conjugated biotherapeutics services.

The business model is a B2B fee-for-service CDMO structure, with quote-based project pricing, multi-year contracts, and direct enterprise engagement with biotech and pharmaceutical clients across Europe, the US, and Asia. The go-to-market combines direct field sales with event-driven lead generation at major industry conferences (Nordic Life Science Days, BioProcess International, BIOSPAIN, CPHI) and content-led demand generation on its website and LinkedIn presence. The company received institutional investment from EQT in 2018 and rebranded to the unified 3PBIOVIAN identity in 2024. Legal entity is 3P BIOPHARMACEUTICALS, S.L.U., a Spanish private limited company (Sociedad Limitada Unipersonal). Revenue, ownership composition, and customer-level data are not publicly disclosed.

Biovian firmographics

Firmographics
Name
Biovian
Legal name
3P BIOPHARMACEUTICALS, S.L.U.
Website
https://biovian.com
Company type
Private
Founded year
2003
Operating status
Operating
Headcount range
101–250 employees
Short description
Biovian (3PBIOVIAN) is a privately-held European biologics CDMO providing GMP contract development and manufacturing services for recombinant proteins, viral vectors (AAV, adenovirus), plasmid DNA, and cell therapies to biotech and pharmaceutical clients globally.
Ownership category
akta.pro rank

Biovian industry classification

Industry
Product category
Biologics Contract Development and Manufacturing
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Scientific Research and Development Services (5417)
SIC
Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGAGAB
Gene Therapy CDMO (Viral Vector Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAGAC
mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGAGAL
GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)

Keywords

  • Biologics contract manufacturing
  • Viral vector manufacturing
  • Recombinant protein production
  • Plasmid DNA manufacturing
  • Cell therapy CDMO

Where Biovian is headquartered

Location

Headquarters

HQ city
Turku
HQ country
Finland
HQ region
Europe

Offices2 records

Markets served

Biovian business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Supply Chain, Technology or R&D, Marketing or Sales

Revenue model

  1. Contract Manufacturing Services: Biovian generates revenue through contract development and manufacturing services. As a CDMO, they provide fee-for-service manufacturing across the product lifecycle, from pre-clinical and clinical development through commercial manufacturing. Revenue is generated through project-based contracts, long-term manufacturing agreements, and development service contracts with biotech and pharmaceutical clients requiring GMP-compliant production of biologics, viral vectors, plasmid DNA, and cell therapies.
  2. Development and Testing Services: Additional revenue streams include process development services, analytical testing and QC services, aseptic fill and finish services, and conjugated biotherapeutics development. These specialized services support the core manufacturing business and provide integrated solutions for clients throughout the drug development journey.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom project-based pricing for CDMO services

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Biovian product offering

Product offering

Core offering

Biovian (3PBIOVIAN) is a Contract Development and Manufacturing Organization (CDMO) providing GMP-compliant biologics manufacturing services from early-stage development through commercial supply. The company offers integrated services across recombinant proteins (microbial and mammalian), viral vectors (AAV, adenovirus), plasmid DNA, and cell therapies, supported by aseptic fill and finish, QC testing, and conjugated biotherapeutics capabilities. Operations are run from two manufacturing sites in Turku, Finland and Pamplona-Noáin, Spain, serving biotech and pharmaceutical clients globally.

Product overview

3PBIOVIAN is a global Contract Development and Manufacturing Organization (CDMO) offering integrated biologics manufacturing services from early-stage development through commercialization. The portfolio spans four core service areas: Proteins (microbial and mammalian expression systems), Viral Vectors (including AAV via the proprietary AAVion® Platform, and adenovirus), Plasmid DNA, and Cell Therapies. These core services are supported by additional capabilities including Aseptic Fill & Finish, QC Services, and Conjugated Biotherapeutics. The company provides end-to-end development and manufacturing for both Drug Substances and Drug Products, serving clients across preclinical, clinical (Phase I-III), and commercial phases. Manufacturing facilities are located in Pamplona-Noáin, Spain and Turku, Finland.

Differentiator

Problem solved

Functional benefit

Brands

  • AAVion® Platform: Proprietary AAV manufacturing platform for gene therapy vector production.

Products and services

  • Recombinant Protein Manufacturing GMP-compliant recombinant protein manufacturing services covering microbial (bacterial) and mammalian (CHO) expression systems for pre-clinical, clinical (Phase I-III), and commercial production. Intended for biotech and pharmaceutical companies developing protein-based biologics.
  • Viral Vector Manufacturing GMP viral vector manufacturing services for gene therapy and vaccine development, including adeno-associated virus (AAV) and adenovirus production for pre-clinical through commercial supply. Target customers are gene therapy developers and vaccine developers in biotech and pharma.
  • AAVion® AAV Manufacturing Platform Proprietary AAV (Adeno-Associated Virus) manufacturing platform enabling flexible and efficient viral vector production for gene therapy applications. Used as the in-house platform for Biovian's AAV manufacturing service line.
  • Plasmid DNA Manufacturing GMP plasmid DNA CDMO services for pre-clinical, clinical, and commercial production following the same GMP standards applied to drug substance and drug product manufacturing. Targeted at developers of gene therapies, DNA vaccines, and cell therapies.
  • Cell Therapy Manufacturing Cell and gene therapy services supporting development, manufacturing, and commercialization of cell-based therapies for biotech and pharmaceutical clients.
  • Aseptic Fill & Finish Integrated aseptic fill and finish services for drug products including formulation, terminal sterilization or aseptic processing, visual inspection, in-house sterility testing, labeling, packaging, and Qualified Person (QP) certified release.
  • Quality Control (QC) Services Quality control testing services supporting biopharmaceutical manufacturing compliance, including analytical and release testing for drug substance and drug product.
  • Conjugated Biotherapeutics Manufacturing Manufacturing services for conjugated biotherapeutics combining biologic components with targeting agents, such as antibody-drug conjugates and related modalities.

Companies that use Biovian

Customer profile

Segments2 records

Ideal customer profiles2 records

Biovian technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Biovian partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Biovian competitors and assessment

Company assessment

Broad incumbents

  • Lonza Group: Global Tier-1 CDMO with massive biologics, viral vector, and cell therapy capacity. Competes head-to-head with Biovian for gene therapy and mammalian protein programs but at vastly larger scale.
  • Samsung Biologics: Large-scale Korean CDMO focused on mammalian biologics manufacturing with rapidly expanding gene therapy services. Represents the scale competition that Biovian faces in winning commercial-stage programs.
  • Thermo Fisher Scientific (Patheon): Global pharma services platform with biologics CDMO, viral vector, and fill-finish capabilities. Competes with Biovian across multiple modalities through its Patheon and Brammer Bio heritage.
  • WuXi Biologics: China-based global biologics CDMO with end-to-end capabilities from cell line development to commercial manufacturing. Direct competitor for biotech outsourcing decisions, including plasmid and viral vector services.
  • Catalent: Global CDMO with biologics, viral vector, and cell therapy capabilities alongside its dominant fill-finish business. Competes with Biovian for biologics manufacturing and integrated DS-to-DP programs.

Direct peers

  • AGC Biologics: Mid-to-large global CDMO offering microbial and mammalian protein, viral vector, and cell therapy services. One of the closest direct peers to Biovian by modality mix and target client base.
  • Rentschler Biologics: European-based CDMO specializing in mammalian cell culture recombinant proteins and gene therapy manufacturing. Closely comparable mid-sized European CDMO competing for the same biotech clients.
  • Vibalogics: Specialist viral vector CDMO focused on late-stage clinical and commercial GMP manufacturing of oncolytic viruses and viral vaccines. Highly comparable to Biovian's viral vector service line.
  • Cobra Biologics (Charles River Laboratories): European CDMO providing viral vector and plasmid DNA manufacturing services for gene therapy and vaccine clients, now part of Charles River. Closely aligned with Biovian's plasmid and viral vector CDMO offering.
  • Yposkesi: French gene therapy CDMO producing AAV and lentiviral vectors for clinical and commercial supply. Comparable European specialty viral vector CDMO competing in the same gene therapy client segment as Biovian.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Biovian social profiles

Digital presence

Biovian financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Biovian leadership team

Management profile

Number of profiles

Profiles2 records

Biovian funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Biovian M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biovian

What does Biovian do?

Biovian (3PBIOVIAN) is a Contract Development and Manufacturing Organization (CDMO) providing GMP-compliant biologics manufacturing services from early-stage development through commercial supply. The company offers integrated services across recombinant proteins (microbial and mammalian), viral vectors (AAV, adenovirus), plasmid DNA, and cell therapies, supported by aseptic fill and finish, QC testing, and conjugated biotherapeutics capabilities. Operations are run from two manufacturing sites in Turku, Finland and Pamplona-Noáin, Spain, serving biotech and pharmaceutical clients globally.

Is Biovian a public or private company?

Biovian is a private company. It is classified as private equity controlled and is currently operating.

When was Biovian founded?

Biovian was founded in 2003. It employs 101 to 250 people.

Where is Biovian based?

Biovian is headquartered in Turku, Finland, in the Europe region.

How does Biovian make money?

Two revenue lines are on record. Contract Manufacturing Services are the primary driver. The others are development and Testing Services.

Who are Biovian's main competitors?

Broad incumbents on record are Lonza Group, Samsung Biologics, Thermo Fisher Scientific (Patheon), WuXi Biologics and Catalent. Direct peers are AGC Biologics, Rentschler Biologics, Vibalogics, Cobra Biologics (Charles River Laboratories) and Yposkesi.

Does Biovian have an API?

No public API is recorded for Biovian.

What industry is Biovian in?

Biovian's product category is Biologics Contract Development and Manufacturing. Its primary akta.pro industry code is HLAGAGAB, Gene Therapy CDMO (Viral Vector Manufacturing), with a secondary code of HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Labiotech.euGene therapy: can CDMOs solve the manufacturing bottleneck?The gene therapy market is experiencing rapid growth driven by numerous FDA approvals and expanding clinical trials, creating a significant manufacturing bottleneck for viral vectors. Biovian, a contract manufacturing organization, has expanded its GMP production capacity with new bioreactors and automated filling lines to address the rising demand from biotech clients.PR NewswireEurocine Vaccines has selected Biovian as contract developer for the chlamydia vaccine candidateEurocine Vaccines AB has selected Biovian Oy, a contract developer and manufacturer based in Turku, Finland, to develop an industrial manufacturing method and manufacture study products for the Company's chlamydia vaccine candidate. The collaboration will begin in January 2021 under an agreement signed December 30, 2020, with activities totaling approximately SEK 9.5 million (EUR 0.94 million) and initially lasting until November 2021. Biovian brings its own GMP facility to support Eurocine Vaccines' toxicological and clinical studies.news.cision.comEurocine Vaccines has selected Biovian as contract developer for the chlamydia vaccine candidateEurocine Vaccines selected Biovian as contract developer for its chlamydia vaccine candidate, with development of manufacturing methods and study products. The collaboration, signed on 30 December 2020, costs about SEK 9.5 million (EUR 0.94 million) and runs until November 2021, with intent to continue until project completion.NatureBiovian: a true one-stop-shop CDMO with gene therapy capacity and a Nordic ethosBiovian, a Finnish CDMO, offers a one-stop-shop service covering the full supply and value chains for medical therapies, including gene therapy. It expanded its viral vector manufacturing capacity in 2020 and added plasmid production, and will open an aseptic filling line in 2021.